Considering some successful clinical trials targeting the TIM3 in cancer [96], theoretically it could be also possible to prevent the exhaustion and thus restore the effective T cell response to SARS-CoV-2 infection especially in patients with critical condition. The gene discussed is HAVCR2; the disease is cancer.